Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Merger or Acquisition (February 2022)
11 slides from Collegium Pharmaceutical's merger presentation, Feb 14, 2022
Slide 1: Collegium to Acquire BDSI
Collegium to Acquire BDSI February 14, 2022
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat
Slide 3: Building a Leading, Diversified Specialty Pharmaceutical Company
A leader in responsible pain management Three commercial - stage assets Strong financial position Delivering value to our shareholders …and we are focused on building the Collegium of tomorrow We are proud of the Collegium we have built … 3 Committed to improving the lives of people suffering from s
Slide 4: Agenda
O PPORTUNITY & S TRATEGIC R ATIONALE Agenda Joe Ciaffoni Chief Executive Officer F INANCIAL O VERVIEW & T RANSACTION D ETAILS Colleen Tupper Chief Financial Officer Q&A Joe Ciaffoni, Chief Executive Officer Colleen Tupper, Chief Financial Officer Scott Dreyer, Chief Commercial Officer 01. 02. 03. 4
Slide 5: 2022: A Pivotal Year for Collegium Pharmaceutical
C RITICAL P RIORITIES • Renegotiate XER Contracts (accounting for ~50% of total prescriptions) • Manage Xtampza ER GtN to <65% (beginning in January 2023) 2022: A Pivotal Year for Collegium Pharmaceutical | X TAMPZA ER C ONTRACT R ENEGOTIATIONS B USINESS D EVELOPMENT A CQUISITIONS • Diversify our po
Slide 6: BDSI Acquisition will Propel Collegium to the Next Level
C OMMERCIAL S TAGE H IGH - S YNERGY Differentiated commercial - stage pain assets Accretive within 24 months N ON - O PIOID P AIN Novel non - opioid pain assets Phase 2 or later assets Potential revenue generation between 2025 - 2027 Peak sales potential of $150 million or greater C OMMERCIAL S TAGE
Slide 7: Transaction Rationale: Strategically and Financially Transformative
P ORTFOLIO & F INANCIAL D IVERSIFICATION • Doubles the number of commercial stage assets • Expands Collegium portfolio of differentiated pain solutions • Results in 2 durable growth drivers, 3 contributors to the top and bottom line, and a launch opportunity • Establishes a foothold in neurology I M
Slide 8: Transaction Details
8 Transaction Details Consideration Under the terms of the definitive agreement, Collegium will commence a tender offer to acquire all the outstanding shares of BDS I at the price of $5.60 per share The offer price of $5.60 represents a 54% premium to BDSI closing share price of $3.64 as of Friday,
Slide 9: Significantly Enhancing Collegium's Financial Profile
Significantly Enhancing Collegium’s Financial Profile D IVERSIFICATION & E XPANSION OF R EVENUES Transaction will be margin accretive day 1 driven by the diversification and expansion of our revenues S IGNIFICANT O PERATIONAL S YNERGIES To be recognized throughout 2022 as we integrate BDSI, and expe
Slide 10: Q&A
Q&A
Slide 11: Thank You
A <@® Collegium Thank You February
Collegium Pharmaceutical — Merger or Acquisition (February 2022) on 6ix